Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Aug 8;25(1):829.
doi: 10.1186/s12884-025-07918-0.

Multidisciplinary, whole-process management of a patient with recurrent serous borderline ovarian tumor from embryo cryopreservation before re-fertility-sparing surgery to successful delivery: a case report

Affiliations
Case Reports

Multidisciplinary, whole-process management of a patient with recurrent serous borderline ovarian tumor from embryo cryopreservation before re-fertility-sparing surgery to successful delivery: a case report

Qin Xu et al. BMC Pregnancy Childbirth. .

Abstract

Background: For patients with recurrent serous borderline ovarian tumors (BOT) who have undergone unilateral salpingo-oophorectomy, there is a risk of reduced or even lost ovarian reserve after the second surgery; therefore, fertility preservation (FP) prior to re-operation in patients of childbearing age is challenging, and has attracted increasing attention. Here, we discuss the multidisciplinary whole-process management of a patient with recurrent serous BOT, from embryo cryopreservation (EC) before re-fertility-sparing surgery (re-FSS) to successful delivery.

Case presentation: We describe the treatment of a 28-year-old married, nulliparous female with recurrent serous BOT who requested FP. The patient underwent right salpingo-oophorectomy in July 2020 for serous BOT. In March 2023, B-ultrasound indicated BOT recurrence, and she underwent a second operation. After a multidisciplinary discussion and information on the risks, the patient strongly requested EC. We used letrozole (LE) combined with an antagonist for ovarian stimulation; 16 eggs were obtained, 15 eggs were MII, four embryos on the 3rd day and one blastocyst was formed and cryopreserved. One month later, laparoscopic cystectomy was performed, and pathological examination revealed serous BOT. Three months after the operation, resuscitation and transplantation of one blastocyst did not result in pregnancy through the natural cycle (NC), followed by resuscitation and transfer of two embryos on day 3 through hormone replacement therapy (HRT), which resulted in a successful pregnancy and live healthy male birth. No recurrence was reported at 19 months after re-FSS.

Conclusions: This case highlights the key points of comprehensive multidisciplinary management from the discovery of BOT recurrence, multidisciplinary team (MDT) consultation, ovarian stimulation (OS), egg retrieval, EC, re-FSS, frozen embryo transfer (FET), to delivery. Re-FSS is safe and effective for patients with recurrent serous BOT and strong fertility requirements, and EC before re-FSS is feasible.

Keywords: Borderline ovarian tumor (BOT); Case report; Embryo cryopreservation (EC); Multidisciplinary team (MDT); Re-fertility-sparing surgery (re-FSS).

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the Medical Ethics Committee of First People’s Hospital of Yunnan Province (number: 2024-GN013). All the patients agreed to participate in the study. Consent for publication: Written informed consent for publication was obtained from the patient. The hospital ethics committee approved the publication of this manuscript. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Examination and surgical results. A On March 23, 2023, B-ultrasound showed a mixed mass in the left ovary (LOV), approximately 33 mm × 25 mm in size, an irregularly shaped solid part, visible papillae, and polycystic changes. B Results of B-ultrasonography on the day of OPU before egg retrieval. Red arrows in A and B highlight the puncture path for oocyte pick-up (OPU). C B-ultrasonography results on the day of OPU after egg retrieval. D LOV appearance during laparoscopy. E Pathological examination
Fig. 2
Fig. 2
Patient treatment course
Fig. 3
Fig. 3
Questions that need to be discussed step-by-step by the MDT for embryo cryopreservation before FSS in BOT patients and our answers for the patient in this case. MDT, multidisciplinary team; FSS, fertility-sparing surgery; BOT, borderline ovarian tumor; FP, fertility preservation; re-FSS, re-fertility-sparing surgery; LE, letrozole; OS, ovarian stimulation; OPU, oocyte pick-up; FET, frozen embryo transfer

Similar articles

References

    1. Gracia M, Alonso-Espías M, Zapardiel I. Current limits of conservative treatment in ovarian cancer. Curr Opin Oncol. 2023;35:389–93. - PubMed
    1. Della Corte L, Cafasso V, Mercorio A, Vizzielli G, Conte C, Giampaolino P. Management of borderline ovarian tumor: the best treatment is a real challenge in the era of precision medicine. Front Surg. 2023;10: 1167561. - PMC - PubMed
    1. Tortajada Valle M, Agustí N, Fusté P, Mensión E, Díaz-Feijóo B, Glickman A, Marina T, Torné A. Laparoscopic fertility-sparing management of borderline ovarian tumors: surgical and long-term oncological outcomes. J Clin Med. 2024. 10.3390/jcm13185458. - PMC - PubMed
    1. Fertility Preservation in Individuals with Cancer. A joint position statement from APHON, CANO/ACIO, and ONS. Can Oncol Nurs J. 2024;34:421–6. - PMC - PubMed
    1. Morice P, Scambia G, Abu-Rustum NR, Acien M, Arena A, Brucker S, Cheong Y, Collinet P, Fanfani F, Filippi F, Eriksson AGZ, Gouy S, Harter P, Matias-Guiu X, Pados G, Pakiz M, Querleu D, Rodolakis A, Rousset-Jablonski C, Stepanyan A, Testa AC, Macklon KT, Tsolakidis D, De Vos M, Planchamp F, Grynberg M. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. Lancet Oncol. 2024;25:e602–10. - PubMed

Publication types

LinkOut - more resources